Transcenta Holding (HKSE:06628) WACC %:13.75% (As of Sep. 11, 2026) — 75% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06628 Transcenta Holding Ltd HKSE:06628
40 GF Score
Price HK$0.91
GF Value HK$0.29
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Transcenta Holding WACC %?

Transcenta Holding HKSE:06628 +7.06% 40 WACC % is 13.75% as of Sep. 11, 2026, which is 75% above its 10-year median of 7.87. GuruFocus rates HKSE:06628 with a GF Score™ of 40/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,420 Biotechnology companies, Transcenta Holding ranks worse than 78.94% on this metric.

As of today (2026-09-11), Transcenta Holding's weighted average cost of capital is 13.75%%. Transcenta Holding's ROIC % is -16.91% (calculated using TTM income statement data). Transcenta Holding earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Transcenta Holding  (HKSE:06628) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Transcenta Holding's weighted average cost of capital is 13.75%%. Transcenta Holding's ROIC % is -16.91% (calculated using TTM income statement data). Transcenta Holding earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

Transcenta Holding WACC % Historical Data

* Premium members only.

The historical data trend for Transcenta Holding's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transcenta Holding WACC % Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial 7.29 8.44 8.49 2.84 13.68

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.49 7.69 2.84 6.21 13.68

HKSE:06628 vs VRTX, REGN, MRNA: WACC % Comparison

For the Biotechnology subindustry, Transcenta Holding's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's WACC % distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's WACC % falls into.


HKSE:06628
40GF Score
Transcenta Holding Ltd HKSE:06628
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transcenta Holding WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Transcenta Holding's market capitalization (E) is HK$387.839 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, Transcenta Holding's latest one-year semi-annual average Book Value of Debt (D) is HK$212.2497 Mil.
a) weight of equity = E / (E + D) = 387.839 / (387.839 + 212.2497) = 0.6463
b) weight of debt = D / (E + D) = 212.2497 / (387.839 + 212.2497) = 0.3537

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.946%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Transcenta Holding's beta is 2.4162.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.946% + 2.4162 * 6% = 19.4432%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Dec. 2025, Transcenta Holding's interest expense (positive number) was HK$7.113 Mil. Its total Book Value of Debt (D) is HK$212.2497 Mil.
Cost of Debt = 7.113 / 212.2497 = 3.3512%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -0.274 / -224.054 = 0.12%.

Transcenta Holding's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.6463*19.4432%+0.3537*3.3512%*(1 - 0.12%)
=13.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 13.75% mean?
Transcenta Holding (HKSE:06628) has a WACC % of 13.75% as of Sep. 11, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Transcenta Holding and its competitors. This is 75% above median its historical median of 7.87. Over the past decade, Transcenta Holding's WACC % has ranged from 2.84 to 14.07. According to the industry distribution chart, Transcenta Holding ranks #1121 out of 1420 companies in the Biotechnology industry, placing it in the top 78.9%.
Is Transcenta Holding's WACC % too high?
Transcenta Holding's current WACC % of 13.75% is 75% above median its 10-year median of 7.87. Over the past 10 years, this metric has ranged from a low of 2.84 to a high of 14.07. The Biotechnology industry median WACC % is 10.19. Transcenta Holding's value of 13.75% is 35% above this industry median. Based on the distribution chart, Transcenta Holding ranks #1121 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transcenta Holding ranks #1121 out of 1420 companies for WACC %. This places Transcenta Holding in the lower half of its industry. The industry median WACC % is 10.19. Transcenta Holding's value of 13.75% is 35% above this benchmark. Historically, Transcenta Holding's own WACC % has ranged from 2.84 to 14.07 over the past decade. While the company's 10-year median is 7.87 vs. the industry median of 10.19, Transcenta Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.19, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transcenta Holding's current WACC % of 13.75% is 35% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Transcenta Holding and its competitors. For the Biotechnology industry, the median WACC % is 10.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transcenta Holding's current WACC % is 13.75%, which is 75% above median its own 10-year median of 7.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current WACC % is 13.75%, which is 75% above median its 10-year median of 7.87 and 35% above the Biotechnology industry median of 10.19. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current WACC % is 13.75% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transcenta Holding (HKSE:06628) Overvalued in 2026?

Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued. The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29. GuruFocus considers Transcenta Holding to be Significantly Overvalued.

Key valuation signals for HKSE:06628:

  • WACC %: 13.75% (75% above median its 10-year median of 7.87)
  • GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
  • GF Score™: 40/100 with 6 warning signs
  • Industry Position: 35% above the Biotechnology median (#1121 of 1420)

No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Transcenta Holding Business Description

Address B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score

Get the complete analysis for HKSE:06628

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.91
Price
HK$0.29
GF Value